HyRAS study


Hypitat Risk Assessment Study. A 2-year follow up to the Hypitat study.


Welcome to the HyRAS website.



20-05-2011  HyRAS wint Eerste Prijs Moderated Postersessie Gynaecongres Zwolle

20-12-2010 Oral presentation en Poster presentation op SGI 2011

Goed nieuws voor de HyRAS! Voor het jaarlijkse congres van de SGI in maart 2011 in Miami is de HyRAS studie geselecteerd voor een oral (abstract: Classic Cardiovascular Risk Factors 2  Years after Pregnancy Complicated by Hypertensive Disease at Term) en een poster presentatie! (abstract: Hypertension 6 Weeks and 2 Years after Term Pregnancies Complicated by Hypertensive Disorders) Heel veel dank voor alle inzet en hulp bij de inclusies!

04-12-2010 Wetenschapsprijs MCH 2010

Op 26 november zijn de eerste resultaten van de HyRAS op de wetenschapsmiddag in het Medisch Centrum Haaglanden in Den Haag gepresenteerd. Deze presentatie heeft de wetenschapsprijs 2010 gewonnen. Hartelijk dank iedereen voor de geweldige bijdrage aan dit succes!


02-12- 2010 Poster presentation SMFM

Goed nieuws! Voor het jaarlijkse congres van de Society of Maternal and Fetal Medicine is de HyRAS studie geselecteerd voor een poster presentatie! Heel veel dank aan iedereen die hard heeft meegewerkt om dit voor elkaar te krijgen.


november 2010. HyRAS inclusies compleet!!

Geweldig! 406 inclusies voor de HyRAS.

De HyRAS-projectgroep wil iedereen die heeft meegewerkt aan dit fantastische resultaat hartelijk bedanken!



Study information



Secondary prevention of cardiovascular disease (CVD) is difficult, partly due to the lack of an effective strategy to identify individuals at high risk, at an age young enough to benefit from preventive interventions. This study follows a high risk strategy, using the novel concept of pregnancy as a cardiovascular challenge test. Ten to fifteen percent of pregnant women experience gestational

hypertension (GH) or preeclampsia (PE) at term. These women have been demonstrated to be at increased risk to develop CVD later in life.



(i) To screen women who have experienced GH or PE at term for risk factors for CVD, two years after their complicated pregnancy. (ii) To estimate the 10-year cardiovascular event risk in these women using validated prediction algorithms, in order to establish the proportion that is likely to benefit from preventive interventions, according to widely accepted guidelines.


Design, setting, and participants

Case control study in the 35 Dutch hospitals participating in the nationwide HYPITAT-study. Participants will be 1200 women of Dutch and foreign origin.



Age, ethnicity, smoking status, antihypertensive medication, parental history of (premature) cardiovascular events, systolic blood pressure, body height, body weight, and waist and hip circumference, and fasting levels of total plasma cholesterol, HDL cholesterol, triglycerides, hs CRP, insulin, glucose, and HbA1c and microalbuminuria will be determined two years after pregnancy. Individual 10-year cardiovascular event risks will be estimated using the Adult Treatment Panel III risk score, Reynolds Risk Score and QRISK.


Knowledge transfer

Design of a future intervention study, to evaluate the feasibility and effectiveness of preventive strategies in women who experience term GH or PE and have a 10-year cardiovascular event risk >10%. Furthermore the result will be submitted to national and international peer reviewed journals.



Duration of the study is 24 months


Project group
Dr. C.J.M. de Groot

Dr. A. Franx

Dr. K.W.M. Bloemenkamp

Dr. M. van Pampus

Dr. B.W. Mol



Nuts/Ohra Stichting